is suggested for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
Recommended dosage: When initiating treatment with Exalgo, health care providers need to consider the daily dose, potency, and specific characteristics of the opioid the patient had previously been taking, as well as the patient's degree of opioid tolerance, age, general condition, and medical status.
Drug interactions: As with other opioid analgesics, Exalgo is not recommended to be used in combination with other central nervous system depressants (including alcohol), monoamine oxidase inhibitors, or opioid antagonists.
CombinatoRx has the potential to create a thriving biopharmaceutical business based on the nearer-term revenue-generating potential of our partnered product assets, such as Exalgo
and Prednisporin, while focusing internal efforts on key programs in our product pipeline with the highest likelihood of creating value going forward.
Covidien said Exalgo
recently met its goal in a late stage clinical trial, and the Food and Drug Administration is scheduled to rule on the drug's approval by Nov.
If approved, it will be marketed by Covidien as Exalgo
and will be the only extended-release formulation of the drug.
8 mg, 12 mg and 16 mg and can be substituted with the full expectation that it will produce the same clinical effect and safety profile when used under the conditions specified in the labeling.
The increase in revenue from the 2011 to the 2012 period was primarily due to increased Exalgo
royalties from Covidien and increased collaborative revenue from Novartis.
By providing a variety of tablet strengths of EXALGO
, physicians and patients can work together to develop and tailor a treatment regimen that optimally controls their pain.
can be abused in a manner similar to other opioid agonists, legal or illicit.
patents relating to Exalgo
to sell Actavis' 32 mg product starting on May 15, 2014.
PRODUCT INNOVATIONS/INTRODUCTIONS II-31Venus Remedies to Unveil Aceclofenac OD II-31Sandoz International Launches Metaxalone Tablets in US II-31Covidien Unveils EXALGO
(TM) Extended-Release Tablets II-31Bresslergroup Develops Dental Vibe for Pain-Free DentalInjections II-32Competitive Technologies Launches Calmare Medical Device II-32Victory Pharma Unveils Naprelan Dose Card II-32BIOLASE Technology Launches Diolase 10(TM) Diode Laser II-33Dr.
1 million in royalty revenue from Covidien based on Exalgo
sales for the quarter ended March 31, 2012.
Time to maximal plasma concentration of HM following administration of PF329 is approximately two hours, slower than immediate release HM and more rapid than the published data for the commercial, once-per-day HM product, Exalgo
Mallinckrodt Acquires Rights of Exalgo